Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 16/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14097557 | 0.90 | ABL1 (0.67) | ABL1 | |
| SCHEMBL14097614 | 0.89 | ABL1 (0.84) | ABL1 | |
| SCHEMBL14097547 | 0.88 | ABL1 (0.86) | ABL1 | |
| SCHEMBL14097584 | 0.87 | ABL1 (0.64) | ABL1 | |
| SCHEMBL14097626 | 0.86 | ABL1 (0.67) | ABL1 | |
| SCHEMBL14097507 | 0.85 | ABL1 (0.61) | ABL1 | |
| SCHEMBL14097401 | 0.85 | ABL1 (0.61) | ABL1 | |
| SCHEMBL14097588 | 0.85 | ABL1 (0.61) | ABL1 | |
| SCHEMBL14097497 | 0.84 | ABL1 (0.60) | ABL1 | |
| SCHEMBL14097395 | 0.84 | ABL1 (0.62) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414046-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414046-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414046-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-19 | — | — | US | disclosed |
| US-RE40245-E1 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-15 | — | — | US | disclosed |
| US-RE40245-E1 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-15 | — | — | US | disclosed |
| US-RE40245-E1 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-15 | — | — | US | disclosed |
| EP-1341769-B1 | BACTERIAL GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2007-10-17 | — | — | EP | disclosed |
| EP-1341769-B1 | BACTERIAL GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20040043989-A1 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-03-04 | — | — | US | disclosed |
| US-6632809-B2 | Bactericides | VERTEX PHARMACEUTICALS INCORPORATED | 2003-10-14 | — | — | US | disclosed |
| EP-1341769-A2 | BACTERIAL GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20030119868-A1 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-06-26 | — | — | US | disclosed |
| WO-2002060879-A2 | BACTERIAL GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119868-A1 | Gyrase inhibitors and uses thereof | TOP1, NQO2, FEN1 | ABL1 1496/4885 |
| US-20040043989-A1 | Gyrase inhibitors and uses thereof | TOP1, NQO2, FEN1 | ABL1 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.